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Abstract
A call from the EU for the set-up of European Reference Networks (ERNs) is expected to be launched in the first
quarter of 2016. ERNs are intended to improve the care for patients with low prevalent or rare diseases
throughout the EU by, among other things, facilitating the pooling and exchange of experience and
knowledge and the development of protocols and guidelines. In the past, for example where costly orphan
drugs have been concerned, industry has played an important role in facilitating consensus meetings and
publication of guidelines. The ERNs should provide a unique opportunity for healthcare professionals and
patients to lead these activities in an independent way. However, currently costs for networking activities are
not to be covered by EU funds and alternative sources of funding are being explored. There is growing
concern that any involvement of the industry in the funding of ERNs and their core activities may create a
risk of undue influence. To date, the European Commission has not been explicit in how industry will be
engaged in ERNs. We believe that public funding and a conflict of interest policy are needed at the level of
the ERNs, Centers of Expertise (CEs), healthcare professionals and patient organizations with the aim of maintaining
scientific integrity and independence. Specific attention is needed where it concerns the development of clinical
practice guidelines. A proposal for a conflict of interest policy is presented, which may support the
development of a framework to facilitate collaboration, safeguard professional integrity and to establish and
maintain public acceptability and trust among patients, their organizations and the general public.
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Background
The launch of European Reference Networks (ERNs) for
rare diseases should facilitate collaborations between
centres of expertise (CEs) and improve the quality of
patient care in EU member states and beyond. The call
for the actual establishment of these networks is
expected to be published in early 2016. At the second
conference on ERNs in Lisbon [1], it was clear that there
is no specific guidance from the European Commission
(EC) on the interaction of care providers with the indus-
try in either CEs or ERNs. In addition, at that time the
EC had no plans to provide any funding for these
networks. Whether there will be any financial support
for ERNs at the level of member states is also unclear.
This is unfortunate. The launch of ERNs creates an
opportunity for healthcare professionals and patient
organizations to work together to improve the quality of
care for patients all over Europe, but for this to be
effective, an infrastructure will be required. This will
need financial support, which must be demonstrable
independent of private interest.
The, mainly pharmaceutical, industry currently funds
patient care, third party research and several of the
activities that will become part of the core business of
the ERN. Examples of such support are the set-up of
care pathways, consensus guidelines and awareness
studies in addition to the support of continuing medical
education (CME). While these initiatives have sometimes
led to valuable contributions to patient care, they have
also raised concerns about the increasing participation
and prominent role of the industry in programs that
should be the sole responsibility of healthcare profes-
sionals [2, 3]. Going forward, to avoid any suggestion of
an inappropriate mingling of private and public health
interests, industry should not be directly involved in the
funding or initial set-up of ERNs. Current guidance
contained in EU law and the European Federation of
Pharmaceutical Industries and Associations (EFPIA) code
of conduct may not prove sufficient and we believe that
more focused regulations and public funds are needed to
guarantee the independence and scientific integrity of
networks, member institutions and their collaborators.
European Reference Networks
In directive 2011/24/EU (Directive on the application of
patients’ rights in cross-border healthcare, [4]) the EC
commits itself and the EU member states to “support
the development of European Reference Networks
between healthcare providers and Centres of Expertise
in Member States, in particular in the area of rare
diseases” (Art. 12 and 13). These European Reference
Networks (ERNs) are intended to support care for
patients with low prevalent or rare diseases (RD)
throughout the EU, and should provide the framework
for healthcare pathways for RD patients through a high
level of integrated expertise.
The European Union Committee of Experts in Rare
Diseases (EUCERD), replaced by the Commission Expert
Group on Rare Diseases, has developed recommenda-
tions on quality criteria for centres of expertise for RD
as well as for specific needs for RD ERNs [5–7]. The
core content of these recommendations is in agreement
with the relevant sections of the EC Delegated and
Implementing Acts [8, 9]. These Acts provide the bind-
ing, legal criteria and conditions that ERNs and their
healthcare providers should fulfil, as well as the criteria
for establishing and evaluating ERNs and their members.
In summary, nationally designated centres of expertise
(CEs) are the core participants in RD ERNs, but different
forms of affiliation to an RD ERN (association, collabor-
ation) are allowed for other healthcare providers in
smaller countries. The main purpose of these networks
is to improve clinical care for RD patients by, among
other things, facilitating the pooling and exchange of
experience and knowledge and the development of
protocols and guidelines in order to ensure equal access
to accurate information, appropriate and timely diagno-
sis and highly specialised and high quality care for RD
patients. At a later stage, networks can apply for EU
grants, which may benefit RD research as well. The
Commission Expert Group on Rare Diseases has recom-
mended to group rare diseases in thematic networks [7].
An EU call for the set-up of ERNs is expected for the
first quarter of 2016.
Although the Acts are clear in how ERNs are to be set
up and evaluated, they are not explicit in how industry
can be engaged in ERNs. We believe that to clarify this
issue for the various ERNs is of key importance to
ensure and guarantee the independence of healthcare
providers and the scientific integrity of medical research
is fully guaranteed while allowing for the limited partici-
pation of industry in the work of ERNs where appropri-
ate. Combining the work of ERNs and CEs with industry
while maintaining professional autonomy and integrity
as well as public acceptability and trustworthiness is a
challenge. In the field of inborn errors of metabolism, a
group of rare disorders in which a gene defect has a
clinically significant impact on a metabolic pathway,
initial discussions point to the importance of the subject
and the relevance of conflicts of interest policies for
ERN networks. This position statement is intended as a
first step to support further discussions, which stretches
well beyond our own field.
Objectives
All RD ERNs will be required to deliver added value in
at least three of the objectives listed in Article 12 of the
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Directive on patients’ rights in cross-border healthcare.
In summary these objectives are:
a) To help realise the potential of European cooperation
regarding highly specialised healthcare for patients
and for healthcare systems by exploiting innovations
in medical science and in health technologies;
b) To contribute to the sharing of knowledge regarding
sickness prevention;
c) To facilitate improvements in diagnosis and the
delivery of high-quality, accessible and cost-effective
healthcare for all patients with a particular medical
condition for which expertise and specialized health-
care facilities are concentrated and only available at
a limited number of locations;
d) To maximise the cost-effective use of available
resources by concentrating them where appropriate;
e) To reinforce research, epidemiological surveillance like
registries and provide training for health professionals;
f ) To facilitate the mobility of expertise, virtually or
physically, and to develop, share and spread
information, knowledge and best practice and to foster
developments of the diagnosis and treatment of rare
diseases, within and outside the reference networks;
g) To encourage the development of quality and safety
benchmarks and to help develop and spread best
practice within and outside the network;
h) To help member states with a low number of
patients with a particular medical condition or
lacking technology or expertise to provide highly
specialised services of high quality.
Funding
The financial support allowing the individual CEs and
affiliated centres to deliver healthcare is the responsibil-
ity of the EU member states. However, the set-up and
maintenance of ERNs will involve costs for networking
activities involved in the set-up of clinical guidelines and
protocols including care pathways, development of
consensus guidelines and awareness studies, which is
currently not covered. According to the recommendations
of the EUCERD [5, 6], such network activities should be
part of a sustainable funding support mechanism provided
from EC funds. Currently, however, it is still unclear what
funding for ERN networking will be available and how it
will be raised and allocated. For ERNs to work independ-
ently, public funding is of crucial importance.
Role of healthcare professionals, patient organizations
and industry
Role of healthcare professionals
ERNs are networks of CEs providing healthcare for pa-
tients suffering from rare diseases: healthcare providers
and the professionals working in such organizations will
lead the networks. ERNs will not only need to collabor-
ate with CEs and each other, but also with patient
groups, social care providers, and affiliated research
groups and diagnostic laboratories. ERNs should there-
fore have a robust and clearly defined governance with
oversight structures and comprehensive methods for
evaluation. The coordinating centre of an ERN will need
to have and further develop its capability to coordinate
the network, and this competence should be regularly
evaluated as well.
Role of patient organizations
CEs should collaborate with patient organizations to
bring in the patient perspective. In addition, patient
organizations should play a role in ERNs and their
evaluation. There is an on-going discussion that the role
of patients and patient organizations should be more
robust and better defined at all levels. In several member
states, patient organizations are increasingly involved in
development of care pathways and research, such as in
the French National Plan for Rare Diseases (Plan
National Maladies Rares [10] and the Italian National
Plan for Rare Diseases [11]). Experiences from these
platforms can be used to strengthen the role of patients
and their organizations in ERNs.
Role of industry
As ERNs primarily engage in clinical activities including
the development of clinical guidelines and protocols
such as diagnostic and therapeutic care pathways, there
should be no role for industry in the governance of
ERNs. Yet, for the discovery and development of new
medications and medical devices that improve the
prevention, diagnosis, and treatment of health problems,
research partnerships between industry, academia, public
hospitals and government are essential. Such partner-
ships should be regulated in such a way that principles
of professional autonomy of healthcare providers and
scientific integrity of researchers are preserved and
conflicts of interests are avoided for the ERN as such
and in the member CEs. To prevent such conflicts of
interest and to prudently handle situations in which they
are at stake is not only in the interest of the ERNs,
healthcare professionals and patients, but also in the
interest of industry. For that reason we propose to adopt
basic principles of independence for ERNs and CEs.
Proposal for a conflict of interest policy
Many healthcare professionals have relationships with
industry. The increasing role of patient organizations in
all aspects of patient care has also enhanced their
interactions with industry. Many of these relationships
concern the clinical development of innovative treat-
ments, but industry also supports disease awareness
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activities, diagnostic recommendations and management
guidelines. Even when industry support for such initia-
tives remains solely financial, the relationships involved
carry risks of conflict of interest and undue influence.
These kinds of risks, which are well recognised for indi-
vidual healthcare professionals and institutions or orga-
nizations, will also apply to ERNs. A conflict of interest
policy is therefore needed with the aim of maintaining
the scientific integrity and professional independence of
ERNs and CEs. Such a policy usually includes i) the
disclosure of financial relationships, ii) the prohibition of
certain relationships, and iii) the management of poten-
tial conflicts of interest that have been identified [12]. In
the paragraphs below, we will first give a short descrip-
tion of the concept of conflicts of interest, followed by
an initial proposal for a conflict of interest policy for
ERNs, their participating CEs and the individual health-
care professionals involved.
Conflicts of interest
According to the report of the USA Institute of
Medicine (IOM) Committee on Conflict of Interest in
Medical Research, Education, and Practice a conflict
of interest is a set of circumstances that creates a risk
that the professional judgment or actions regarding a
primary interest (i.e. promoting and protecting the
integrity of research, the welfare of patients, and the
quality of medical education) will be unduly influ-
enced by a secondary interest (i.e. financial interests).
Secondary interests are unwanted only if they are
more important than the primary interest in profes-
sional decision-making [12]. Conflict of interest pol-
icies aim to safeguard that primary interests guide
professional decisions, and not secondary interests.
Such policies have proven to work best when they are
preventive and corrective rather than punitive [12].
Also, the likelihood of undue influence should be
taken into account when developing a conflict of
interest policy [12]. At the level of the individual
healthcare professional, it is assumed that the prob-
ability increases when the value of the secondary
interest is greater. Shareholding (or share options) in
a pharmaceutical company, for example, creates a
great risk for a conflict of interest, since positive
results of a clinical trial may directly benefit the
healthcare professional involved. Likewise, large fees
for serving on a company advisory board carry a
greater risk than small honoraria. Other aspects of
the relationship, such as its depth and duration, may
unduly influence professional decisions; the longer
and closer the relationships, the higher the risk.
Thirdly, whether the payments are transferred to the
personal bank account of the healthcare professional
or to the institution’s account is of importance when
assessing the risk of undue influence [12]. Relation-
ships with industry and conflicts of interest may not
only exist at the individual level, but also at the insti-
tutional level and for patient organizations. For
example, institutions may rely on industry funding for
the appointment of research personnel, the develop-
ment of treatment guidelines, or other activities. Simi-
lar risks may be greater for ERNs as, in the rare
disease field, experts are involved in the development
of innovative therapies and thus almost invariably
have relationships with industry. Going forward,
strategies should be developed which will avoid all
potential conflicts of interest, but in the first instance,
this may be an unrealistic goal. Taking all these
things into consideration we propose the following
recommendations.
Recommendations
Principles and regulations to protect scientific integ-
rity and professional independence should be specified
for (a) the governance of ERNs including the activities
carried out by the ERN; (b) the CEs that will be its
members and their activities; (c) external collaborative
relations of ERNs and CEs with third parties:
(a)ERN governance and activities
 Costs for networking should be funded by the EC
or scientific organizations. Direct funding by
industry should be prohibited.
 ERNs should create a strong governance
structure, with a steering committee, an
independent board of trustees and transparent
procedures to avoid and handle potential
conflicts of interest and the handling of
complaints
 The board of trustees (adapted from [12])
– has no members who themselves have
serious conflicts of interest (see below)
relevant to the activities of the ERN;
– has no members who are directly in charge of
running a CE that is part of the ERN;
– has at least two patient representatives
and a government/EC representative
with relevant expertise;
– creates adequate and independent
arrangements for the day-to-day oversight
and the management of institutional
conflicts of interest;
– submits an annual report to the steering
committee, which should be made public.
 Activities within ERNs, specifically the
development of clinical guidelines and
protocols such as care pathways, treatment
guidelines and diagnostic strategies should
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– follow state of the art methodology, including
the conduct of systematic and up to date
reviews of the evidence and the linking of
recommendations to that evidence
– include members that meet the criteria as
listed in Table 1 [12]
(b) Centres of Expertise and their members
 CEs wishing to join an ERN should disclose their
financial relationships with industry, which will
be assessed against the criteria as delineated in
Table 2
 CEs with serious conflicts of interest according to
the criteria in Table 2 cannot be part of an ERN
 Healthcare professionals involved in CEs and
ERNs should publicly disclose their financial
relationships with industry
 Healthcare professionals involved in CEs and
ERNs with serious conflicts of interest
according to the criteria in Table 2 cannot
participate in the development of clinical
guidelines and protocols such as care
pathways, treatment guidelines and diagnostic
strategies
(c) External collaborative relations with third parties
Public-private partnership in the context of ERNs
should be possible for the stimulation of
innovation, in particular development of new
treatments or medical devices and tools that
ultimately offers benefit to patient care. The industry
is a very valuable partner in this respect. It is
expected that ERNs will engage with industry in
future applications for Horizon 2020 research grants.
These partnerships should be established in such a
way that the principles of independence of an ERN
and the CEs are maintained.
The industry cannot be involved in development
of clinical guidelines and protocols, such as care
pathways, treatment guidelines and diagnostic
strategies, as indicated above, nor can they be
members of the ERN, steering committee or
board of trustees.
Summary
A conflict of interest policy with respect to European
Reference Networks, Centres of Expertise, individual
healthcare professionals and patient organizations is
needed to maintain scientific integrity and independ-
ence of ERNs. We propose criteria for a transparent
structure, which could be used as a guideline for the
future set-up of ERNs. The main elements are [1] a
strong governance, with a Board of Trustees, whose
task will be to monitor the activities and make sure
that independence is maintained, and [2] a clearly
defined set of criteria for CEs and their members.
ERNs should seek endorsement from existing inde-
pendent working groups. After the ERNs have been
established, they can interact with industry for clearly
described projects focusing on basic research. To
Table 1 Proposed criteria for participation in the assessment
and approval of clinical guidelines and protocols for rare
conditions/diseases (adapted from recommendation 7.1 in [12])
Panels and groups that formulate and assess ERN guidelines for clinical
practice should generally exclude as panel members individuals with
conflicts of interest (see Table 2) and should not accept direct funding
from medical product companies or company foundations. Such groups
should publicly disclose with each guideline their conflict of interest
policies and procedures and the sources and amounts of indirect or direct
funding received for development of the guideline. In the situation in
which avoidance of panel members with conflicts of interest is impossible
because of the critical need for their expertise, then groups should:
• Publicly document that they made a good-faith effort to find experts
without conflicts of interest by issuing a public call for members and
other recruitment measures;
• Appoint a chair without a conflict of interest;
• Limit members with conflicting interests to an agreed part of the panel;
• Exclude individuals with serious conflicts of interest (see Table 2);
• P3ublicly disclose the relevant conflicts of interest of panel members.
Table 2 Proposed criteria for conflicts of interest
1. CEs that are members of an ERN can receive unrestricted grants as
well as research grants from a pharmaceutical company provided full
and timely (i.e., advance) disclosure of receiving such grants is given
to the ERN’s Steering Committee and the amount does not conflict
with other criteria
2. Centres of Expertise (CEs) cannot become a member of an ERN if it is
primarily funded by and financially dependent on industry for a
substantial part (to be defined by an independent body)
3. Healthcare professionals and patient representatives involved in CEs
and ERNs cannot take part in the development of clinical guidelines
and protocols, such as care pathways, treatment guidelines and
diagnostic strategies, if they have the following serious conflicts of
interest relevant to the CE or ERN:
a. being employed by a company with commercial interest
b. having equity or other ownership interests in a company with
commercial interest
c. receiving fees for work related activities on a personal bank
account
d. receiving fees that are disproportional to the work done
(i.e., maximum fee more than locally agreed standards per hour)
4. Healthcare professionals and patient representatives involved in CEs
and ERNs can take part in the development of clinical guidelines and
protocols, such as care pathways, treatment guidelines and diagnostic
strategies, if they have the following conflicts of interest, provided
that they fully disclose these relationships and compensation is
reasonable (according to local standards):
a. performing activities in the context of clinical trials
b. performing consultancies for a company
c. giving presentations during meetings organized by a company
d. receiving reasonable reimbursement of travel and hotel costs as
part of meetings organized by a pharmaceutical company
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allow for an independent set-up of ERNs, a strategy
for public funding should be developed by the EC as
soon as possible.
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